Radiolabeled PARP Inhibitors for Imaging and Targeted Radiotherapy of Prostate Cancer
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is a highly lethal disease with no curative therapeutic options. Targeted radiotherapy is a promising approach for treating mCRPC, as demonstrated by the recently Food and Drug Administration-approved 223RaCl2. The 223RaCl2 has shown a survival advantage in this patient population when compared to placebo, even though the radiation is targeted to the tumor microenvironment and not tumor cells themselves. We have developed an agent similar to 223RaCl2 that delivers and accumulates the radiation directly in the tumor cells. This agent can also be tagged with a different type of radioactivity, such that it can be imaged noninvasively to confirm binding to its target. The normal tissue toxicity of such agents is low. We have preliminary data in cells and mouse models indicating this approach will work. This study is directly relevant to cancer patients, as it will develop a novel strategy for treating metastatic prostate cancer. It is anticipated that this approach will have a significant impact on the management of this disease. In addition, this approach can be used in the future to treat other cancers. The funds provided here would allow us to be able to perform studies to progress into the clinic. We anticipate that we would be able to perform patient-related studies in approximately 5 years from the initiation of the grant.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Nov 19, 2019
- Source ID
- W81XWH1910484
Entities
People
- Buck Rogers
Organizations
- United States Army
- Washington University in St. Louis